Docoh
Loading...

AVTX Avalo Therapeutics

Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.

Company profile

Ticker
AVTX
Exchange
Website
CEO
Michael F. Cola
Employees
Incorporated
Location
Fiscal year end
Former names
Cerecor Inc.
SEC CIK
Subsidiaries
Ichorion Therapeutics, LLC • Aevi Genomic Medicine, LLC • Medgenics Medical (Israel) Ltd. • neuroFix, LLC • Aevi Genomic Medicine Europe • TRx Pharmaceuticals, LLC • Zylera Pharmaceuticals, LLC • Zylera Pharma Corp. ...

AVTX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

2 Aug 21
26 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 40.63M 40.63M 40.63M 40.63M 40.63M 40.63M
Cash burn (monthly) (positive/no burn) 414.92K 5.79M 6.46M 6.4M 5.31M
Cash used (since last report) n/a 1.61M 22.49M 25.11M 24.84M 20.63M
Cash remaining n/a 39.01M 18.13M 15.52M 15.78M 19.99M
Runway (months of cash) n/a 94.0 3.1 2.4 2.5 3.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Oct 21 Cola Michael F Stock Option Common Stock Grant Acquire A No No 2.25 78,116 175.76K 78,116
30 Sep 21 Gilla Kaplan Stock Option Common Stock Grant Acquire A No No 2.18 9,541 20.8K 9,541
30 Sep 21 Persson Magnus Stock Option Common Stock Grant Acquire A No No 2.18 5,985 13.05K 5,985
30 Sep 21 Gutry Phil Stock Option Common Stock Grant Acquire A No No 2.18 4,718 10.29K 4,718

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

60.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 70 69 +1.4%
Opened positions 11 15 -26.7%
Closed positions 10 6 +66.7%
Increased positions 31 32 -3.1%
Reduced positions 18 11 +63.6%
13F shares
Current Prev Q Change
Total value 5.41B 197.75M +2634.3%
Total shares 66.75M 59.75M +11.7%
Total puts 104.8K 47.5K +120.6%
Total calls 55.8K 16.7K +234.1%
Total put/call ratio 1.9 2.8 -34.0%
Largest owners
Shares Value Change
Armistice Capital 39.1M $127.86M +19.8%
Nantahala Capital Management 6.33M $20.69M -17.3%
BLK Blackrock 3.69M $12.06M +53.2%
Vanguard 3.2M $10.47M +19.0%
Opaleye Management 1.57M $5.13M -39.7%
Geode Capital Management 1.31M $4.28M +24.1%
Point72 Asset Management 1.3M $4.27M -46.8%
Boothbay Fund Management 1.24M $4.04M 0.0%
Two Sigma Advisers 1.22M $4M +203.1%
Two Sigma Investments 1.13M $3.71M +66.8%
Largest transactions
Shares Bought/sold Change
Armistice Capital 39.1M +6.47M +19.8%
Nantahala Capital Management 6.33M -1.33M -17.3%
BLK Blackrock 3.69M +1.28M +53.2%
Point72 Asset Management 1.3M -1.15M -46.8%
Opaleye Management 1.57M -1.03M -39.7%
Two Sigma Advisers 1.22M +819K +203.1%
Sio Capital Management 0 -552.24K EXIT
Vanguard 3.2M +511.17K +19.0%
Assenagon Asset Management 898.37K +483.26K +116.4%
Two Sigma Investments 1.13M +453.83K +66.8%

Financial report summary

?
Management Discussion
  • Net product revenue was $2.7 million for the three months ended June 30, 2021, as compared to $1.3 million for the three months ended June 30, 2020. During the first quarter of 2021, the Company’s inventory on hand became short-dated (which the Company considers inventory within six months of expiration) due to manufacturing delays and therefore the Company recorded a full sales return allowance on sales of short-dated inventory given the high likelihood of return. The Company received the delayed inventory lot in April 2021 and began selling this lot immediately. As a result, net revenue increased for the three months ended June 30, 2021 as compared to the prior year period due to the increased demand to backfill the short-dated inventory.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: accelerate, acceleration, accretion, Advisory, alpha, Alto, annum, ATM, backfill, baseline, bowel, Burnham, Cantor, channel, check, checkpoint, collateral, colonoscopy, COMTi, consent, correlating, cured, customary, default, deposit, disagreement, Discovery, dramatic, earn, endoscopic, enforcement, factor, failed, failing, Fitzgerald, floor, fundable, genetic, Horizon, immune, immunologic, immunology, insurance, Intellectual, lien, LP, Merck, Michael, MM, moderate, modest, modification, modified, Neuroscience, notified, occurrence, pharmacodynamic, platform, Powerscourt, predetermined, prepay, prepayment, prime, proceeding, rapid, RBC, refractory, Sanford, score, showed, signifying, single, Street, Suzanne, ulcerative, upcoming, venture, waived, Wall, XXV
Removed: acceptance, agreed, application, ascending, billion, core, developed, dosage, Eli, exchanged, explore, hospitalized, inclusive, licensed, Lilly, objective, premium, reaching, representing, retain, safety, tranche, transferred, Watson